KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Castle Biosciences (CSTL) Shares Outstanding (2018 - 2026)

Castle Biosciences' Shares Outstanding history spans 8 years, with the latest figure at $29.7 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 4.22% to $29.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $29.7 million, a 4.22% increase, with the full-year FY2025 number at $29.7 million, up 4.22% from a year prior.
  • Shares Outstanding hit $29.7 million in Q4 2025 for Castle Biosciences, up from $29.2 million in the prior quarter.
  • Over the last five years, Shares Outstanding for CSTL hit a ceiling of $29.7 million in Q4 2025 and a floor of $25.1 million in Q1 2021.
  • Historically, Shares Outstanding has averaged $27.3 million across 5 years, with a median of $27.2 million in 2023.
  • Biggest five-year swings in Shares Outstanding: grew 27.42% in 2021 and later rose 1.72% in 2022.
  • Tracing CSTL's Shares Outstanding over 5 years: stood at $25.4 million in 2021, then grew by 4.63% to $26.6 million in 2022, then rose by 3.23% to $27.4 million in 2023, then increased by 3.91% to $28.5 million in 2024, then increased by 4.22% to $29.7 million in 2025.
  • Business Quant data shows Shares Outstanding for CSTL at $29.7 million in Q4 2025, $29.2 million in Q3 2025, and $29.0 million in Q2 2025.